DS-2969b

Research use only, not for human use.

DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL.

DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL; showes potent in vitro activity against C. difficile clinical isolates with MIC90 of 0.06 μg/mL, 2-, 32-, and 16-fold lower than the MIC90 of fidaxomicin, vancomycin, and metronidazole, respectively; demonstrates excellent in vivo activity against Clostridium difficile (CDI) model.Bacterial Infection Phase 1 Clinical

DS 11960558

GPCR/G Protein

Antibacterial

Antibacterial

Infection

Bacterial Infection

2092352-48-0

428.94

C17H25ClN6O3S

>98% (HPLC)

——

——

4-chloro-5-ethyl-N-{(3S,4R)-1-[5-(2-hydroxypropan-2-yl)-1,3,4-thiadiazol-2-yl]-3-methoxypiperidin-4-yl}-1H-imidazole-2-carboxamide

(-20℃)

With Ice Pack

≥ 2 years